sargramostim
Selected indexed studies
- Sargramostim. (, 2006) [PMID:37856647]
- Sargramostim and immune checkpoint inhibitors: combinatorial therapeutic studies in metastatic melanoma. (Immunotherapy, 2021) [PMID:34157863]
- Sargramostim (rhu GM-CSF) as Cancer Therapy (Systematic Review) and An Immunomodulator. A Drug Before Its Time? (Front Immunol, 2021) [PMID:34484202]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Sargramostim. (2006) pubmed
- Sargramostim and immune checkpoint inhibitors: combinatorial therapeutic studies in metastatic melanoma. (2021) pubmed
- Sargramostim (rhu GM-CSF) as Cancer Therapy (Systematic Review) and An Immunomodulator. A Drug Before Its Time? (2021) pubmed
- Sargramostim for Prophylactic Management of Gastrointestinal Immune-Related Adverse Events of Immune Checkpoint Inhibitor Therapy for Cancer. (2024) pubmed
- Sargramostim in acute radiation syndrome. (2022) pubmed
- Sargramostim (GM-CSF) for induction of remission in Crohn's disease. (2011) pubmed
- Nebulised sargramostim in pulmonary alveolar proteinosis. (2022) pubmed
- Inhaled Sargramostim (Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor) for COVID-19-Associated Acute Hypoxemia: Results of the Phase 2, Randomized, Open-Label Trial (iLeukPulm). (2023) pubmed
- An update on sargramostim for treatment of acute radiation syndrome. (2018) pubmed
- Sargramostim (GM-CSF) for induction of remission in Crohn's disease: a cochrane inflammatory bowel disease and functional bowel disorders systematic review of randomized trials. (2012) pubmed